{"analyses":[{"ciLowerLimit":"0.819","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","estimateComment":"Cabazitaxel 25 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by Eastern Cooperative Oncology Group performance status (ECOG PS) score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7574","pValueComment":"P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479","paramType":"Hazard Ratio (HR)","paramValue":"0.975","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.197","estimateComment":"Cabazitaxel 20 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9967","pValueComment":"P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479","paramType":"Hazard Ratio (HR)","paramValue":"1.009","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.18","upperLimit":"27.60","value":"24.3"},{"groupId":"OG001","lowerLimit":"21.75","upperLimit":"27.20","value":"24.5"},{"groupId":"OG002","lowerLimit":"22.90","upperLimit":"26.97","value":"25.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"389"},{"groupId":"OG002","value":"388"}],"units":"Participants"}],"description":"OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}